• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Pharmaceutical composition for use in the prophylactic and/or therapeutic treatment of dyskinesias induced by L-DOPA. The present invention relates to the pharmaceutical field, more particularly to the use of Rho kinase inhibitors for the treatment or prevention of dyskinesias induced by L-DOPA. (Machine-translation by Google Translate, not legally binding)
    公开号:ES2804076A1
    申请号:ES201930713
    申请日:2019-07-31
    公开日:2021-02-03
    发明作者:Patiño Ana M Muñoz；García José Luis Labandeira；López Andrea López
    申请人:Universidade de Santiago de Compostela；
    IPC主号:
    专利说明:

    [0002] Pharmaceutical composition for use in the prophylactic and / or therapeutic treatment of dyskinesias induced by L-DOPA
    [0004] Sector of the invention
    [0006] The present invention relates to the pharmaceutical field, more particularly to the use of Rho kinase inhibitors for the treatment or prevention of dyskinesias induced by L-DOPA.
    [0008] Background
    [0010] Parkinson's disease (PD) is one of the most frequent neurodegenerative diseases in our population. It is mainly characterized by motor symptoms that occur due to the degeneration of dopaminergic neurons in the substantia nigra, although other neuron systems are also involved. The usual and to date the most effective treatment for this disease consists of the administration of the precursor molecule of dopamine, L-DOPA. This drug is effective during the first years, but in the longer term it leads to complications and side effects, among which dyskinesias stand out.
    [0012] L-DOPA-induced dyskinesias consist of fast abnormal involuntary movements of the choreic type and athetosis, which usually affect the extremities and sometimes the facial and neck area. Various forms of dyskinesia have been described depending on the temporal pattern of expression: peak-dose dyskinesias (they coincide with the highest plasma levels of dopamine), biphasic dyskinesias and dystonia in the “off” period. These complications can become disabling, since they greatly reduce the therapeutic effect of L-DOPA by limiting the daily activity of patients. It has been described that after 5 years of treatment around 50% of patients suffer from dyskinesias, while at 10 years the percentage rises to 90% (Olanow CW, Stocchi F. Levodopa: A new look at an old friend. Mov Disord (2018) 33 (6): 859-866. doi: 10.1002 / mds.27216).
    [0014] The causes involved in the development of dyskinesias are not entirely known, although the glutamatergic system is known to play an important role. In fact, the The drug currently used to combat dyskinesias is amantadine, an antagonist of NMDA glutamate receptors. However, this compound is contraindicated in cases of kidney failure, heart and psychiatric problems and leads to patients developing complications and numerous side effects such as: lightheadedness, difficulty concentrating, insomnia, loss of appetite, nausea and psychiatric problems (confusion hallucinations , delirium syndrome, psychosis). In the last decade it has been shown that other systems, such as the serotonergic system, are also involved, since in advanced stages of the disease, L-DOPA is transformed into dopamine in the serotonergic terminals and is released in an unregulated manner. But compounds that act at that level, such as serotonin 5-HT1a receptor agonists (buspirone, saritozan, tandospirone) can present problems, since although anti-dyskinetic effects were observed in the first trials, in certain cases they can affect the antiparkinsonian response. Or for example, 5-HT1a / b agonists (eltoprazine and anpirtoline), which have a more favorable pharmacological profile than the previous ones, but could also partially reduce the therapeutic effect of L-DOPA.
    [0016] Thus, it is necessary to research and develop other prophylactic and / or therapeutic treatments to combat dyskinesias, which present fewer side effects and are more effective.
    [0018] Brief description of the invention
    [0020] The results shown in this document demonstrate that the inhibition of the RhoA-Rho kinase (ROCK) pathway makes it possible to treat and / or prevent dyskinesias that can be produced by the chronic treatment of L-DOPA, administered to patients with the disease of Parkinson.
    [0022] Thus, the present invention is directed to a pharmaceutical composition comprising a compound capable of inhibiting ROCK, for use in the prophylactic or therapeutic treatment of dyskinesias induced by L-DOPA.
    [0024] The present invention is further directed to pharmaceutical compositions of ROCK inhibitors, their pharmaceutical form for different routes of administration and to certain useful doses for the prevention of dyskinesias, as well as at certain doses useful for the treatment of dyskinesias.
    [0026] Description of the figures
    [0027] Figure 1 shows the effect of L-DOPA-induced dyskinesias on the RhoA / ROCK pathway in the substantia nigra (A-C) and striatum (D-F). In dyskinetic animals treated with both doses of L-DOPA (6 mg / kg; LD-6 and 12 mg / kg), a significant increase in protein expression for RhoA and ROCK (A, B) and activity for ROCK was observed. (C) in the substantia nigra, while in the striatum the differences were only significant with the high dose (D, E). However, after real-time PCR analysis, significant differences were observed with both doses in the striatum. The results were normalized with respect to the values of the 6-OHDA injured animals treated with saline. Data represented as mean ± SEM, t-Student * p <0.05
    [0029] Figure 2 shows the abnormal involuntary movements (AIMs) observed after chronic treatment with L-DOPA (23 and 32 days) and different doses of Fasudil (10mg / kg; A, C, E and G and 30-40mg; B, D, F, H). In the group of animals co-treated with Fasudil (open circles) a statistically significant reduction of these movements was observed both in the total score (A, B) and in the analysis of the different components: limb (C, D), axial (E, F), orolingual (G, H). Data represented as mean ± SEM (standard error of the mean), t-Student, * p <0.05
    [0031] Figure 3 shows the cylinder test in animals with unilateral dopaminergic lesion where <20% of the use of the left limb is observed in baseline conditions, and recovery of motor asymmetry after injection of L-DOPA at 60 and 90 min in control animals (only L-DOPA; black bars) and in those animals co-treated with Fasudil (gray bars) 10 mg / kg (A), 30 and 40 mg / kg (B). Rotational behavior was also not affected after treatment with Fasudil, indicating that the reduction in dyskinesias is not due to a reduction in motor activity (C-E). Data represented as mean ± SEM, t-Student, * p <0.05
    [0033] Figure 4 shows the effect of ROCK inhibition in animals with a stable degree of dyskinesia (chronic treatment with L-DOPA, 3 weeks). In this case, Fasudil at the low dose (10mg / kg, A) did not produce any effect on dyskinetic movements (A). However, high doses of the compound (30 and 40 mg / kg) resulted in a reduction significant L-DOPA even at the high dose of L-DOPA (24 mg / kg) (B). Data represented as mean ± SEM, t-Student * p <0.05
    [0035] Detailed description of the invention
    [0037] As used in the description and the appended claims the term "ROCK pathway" refers to the pathway in which the RhoA GTPase protein and its associated kinase participate, (also known as Rho-kinase). Rho A binds to a specific ROCK region by activating it. ROCK phosphorylates various target proteins, including the myosin light chain, which acts by reorganizing the actin of the cytoskeleton and regulating apototic events (Amin E, Dubey BN, Zhang SC, Gremer L, Dvorsky R, Moll JM, Taha MS, Nagel- Steger L, Piekorz RP, Somlyo AV, Ahmadian MR (2013) Rho-kinase: regulation, (dys) function, and inhibition. Biol Chem 394: 1399-410. Doi: 10.1515 / hsz-2013-0181.). This pathway is involved in the inflammatory response in certain diseases, including neurodegenerative diseases such as Parkinson's disease. ROCK also acts in autophagy processes and the inhibition of this pathway produces axonal stabilization, leading to neuroprotective effects. Two isoforms encoded by different genes have been described: ROCK I and ROCK II. ROCK II is preferentially expressed in the brain (see as a review, Labandeira-Garcia et al., 2014).
    [0039] As used in the description and the appended claims, the term "compound capable of inhibiting the ROCK pathway" refers to a compound capable of reducing the activity of the enzyme and its expression levels in a statistically significant way with respect to its corresponding controls. those who have not been given the inhibitor. A person skilled in the art can test such inhibition through different methods, such as the measurement of the activity of the ROCK enzyme itself through enzyme-immunoassay techniques (ROCK Activity Assay kit; Cell Biolabs, Inc, San Diego, CA, USA) where myosin phosphorylation, mRNA expression levels are detected by real-time PCR or protein expression levels through Western Blot. These techniques are described in detail in the following publication, which is incorporated in its entirety into the present description: Rodriguez-Perez AI1, Dominguez-Meijide A, Lanciego JL, Guerra MJ, Labandeira-Garcia JL. Inhibition of Rho kinase mediates the neuroprotective effects of estrogen in the MPTP model of Parkinson's disease. Neurobiol Dis. 2013 58: 209-19. doi: 10.1016 / j.nbd.2013.06.004.
    [0040] According to the present invention, a compound capable of inhibiting the ROCK pathway can directly or indirectly regulate the ROCK pathway.
    [0042] As used in the description and the appended claims the term "L-DOPA-induced dyskinesias" is to be understood as abnormal involuntary movements experienced by a mammal (for example human) suffering from Parkinson's disease and being treated with L- DOPA.
    [0044] In the present invention, the authors have investigated the effect that chronic administration of L-DOPA produces at the molecular level in a rat model injured with 6-OHDA, demonstrating that the levels of Rho A and ROCK increased compared to the control (see Figure 1), which implies an activation of this pathway. Under these conditions, at the functional level the rats suffered dyskinesias caused by the chronic treatment of L-DOPA. On the basis of these experiments, a relationship between ROCK pathway activation and dyskinesias is demonstrated for the first time. The authors of the present invention have shown that the regulation of the ROCK pathway has an effect on dyskinesias, so that by inhibiting the ROCK pathway it is possible to reduce the dyskinesias already established in an animal model treated with L-DOPA (see example 4 ) or reduce the development of dyskinesias in an animal model that is started to be treated with L-DOPA (see example 2).
    [0046] Thus, in one aspect the invention is directed to a pharmaceutical composition comprising a compound capable of inhibiting the ROCK pathway, for use in the prophylactic or therapeutic treatment of dyskinesias induced by L-DOPA.
    [0048] In a particular relationship, the composition of the invention is administered in a pharmaceutical form suitable for intraperitoneal, oral or injectable administration. In a particular embodiment, injectable administration comprises intramuscular, subcutaneous, intravenous and intradermal administration.
    [0050] In a particular embodiment, the ROCK inhibitor is selected from Fasudil and its derivatives, Ripasudil, Y-27632, Y-32885, AMA-0076, AR-12286, AR-13324 (Rhopressa), KD-025 (Slx2119), LX7101, PG-324 (Roclatan), SAR407899.
    [0052] In a preferred embodiment, an inhibitor of the ROCK pathway of interest for the present invention is Fasudil. Thus, in a particular embodiment, the invention refers to the pharmaceutical composition described above, where said compound is Fasudil, a pharmaceutically acceptable salt thereof, or a derivative thereof. In another particular embodiment, the Fasudil derivative is selected from Hydroxyfasudil and Dimethylfasudil.
    [0053] The present invention also describes that the administration of Fasudil to an animal model of Parkinson's prior to being treated with L-DOPA, and also if during the treatment with L-DOPA Fasudil is also administered, a preventive result of dyskinesias is achieved, reducing its development throughout the treatment. In example 2, it is also demonstrated that when there is an acute administration of L-DOPA and dyskinesias are more pronounced, treatment with Fasudil is still effective reducing the development of dyskinesias compared to the case without treatment with Fasudil (see example 2 and figure 2).
    [0055] Thus, in a particular embodiment, the invention relates to the pharmaceutical composition of the invention for use in the prophylactic treatment of dyskinesias induced by L-DOPA, comprising: (i) the administration of said pharmaceutical composition in a therapeutically effective amount prior to initiation of treatment with L-DOPA, and (ii) the administration of a therapeutically effective amount of said pharmaceutical composition simultaneously or sequentially to each administration of L-DOPA.
    [0057] In a particular embodiment, the invention refers to a method to prevent dyskinesias induced by L-DOPA, where the patient is suffering from Parkinson's disease, the method comprises administering a therapeutically effective amount of Fasudil prior to the start of L-treatment. DOPA, and administering a therapeutically effective amount of Fasudil simultaneously or sequentially with each administration of L-DOPA.
    [0059] In a particular embodiment, the invention is directed to a pharmaceutical composition of the invention for use in a prophylactic treatment of dyskinesias induced by L-DOPA.
    [0061] In this case, there is also an additional advantage since at this dose Fasudil provides neuroprotection to Parkinson's disease patients and stops dopaminergic degeneration (Villar-Cheda B, Dominguez-Meijide A, Joglar B, Rodriguez-Perez AI, Guerra MJ, Labandeira-Garcia JL. (2012) Involvement of microglial RhoA / Rho-kinase pathway activation in the dopaminergic neuron death. Role of angiotensin via angiotensin type 1 receptors. Neurobiol Dis 47: 268-79 doi: 10.1016 / j.nbd .2012.04.010). And on the other hand, the administration of the composition of the invention for the prevention of dyskinesias has a preferred dosage as described above that also favors the effect neuroprotector del Fasudil (Borrajo A, Rodriguez-Perez AI, Villar-Cheda B, Guerra MJ, Labandeira-Garcia JL. (2014) Inhibition of the microglial response is essential for the neuroprotective effects of Rho-kinase inhibitors on MPTP-induced dopaminergic cell death. Neuropharmacology 85: 1-8 doi: 10.1016 / j.neuropharm.2014.05.021; Villar-Cheda B, Dominguez-Meijide A, Joglar B, Rodriguez-Perez AI, Guerra MJ, Labandeira-Garcia JL. (2012) Involvement of microglial RhoA / Rho-kinase pathway activation in the dopaminergic neuron death. Role of angiotensin via angiotensin type 1 receptors. Neurobiol Dis 47: 268 79 doi: 10.1016 / j.nbd.2012.04.010; Labandeira-Garcia JL, Rodriguez-Perez AI, Villar-Cheda B, Borrajo A, Dominguez-Meijide A, Guerra MJ. (2015) Rho Kinase and Dopaminergic Degeneration: A Promising Therapeutic Target for Parkinson's Disease. Neuroscientist 21: 616-29 doi: 10.1177 / 1073858414554954).
    [0063] The present invention also describes the utility of the compositions of the present invention for the therapeutic treatment of dyskinesias induced by L-DOPA. In example 4 it is demonstrated that even in cases where dyskinesias are already established, the composition with a ROCK inhibitor is capable of reducing them. By increasing the dose of Fasudil (40mg / kg), dyskinesias are reduced to almost 50% in those animals that are already dyskinetic (periodically treated with L-DOPA for 3-4 weeks). And even when after acute administration of L-DOPA, dyskinesias are more reduced when accompanied by the administration of the compositions of the invention.
    [0065] Thus, in a particular embodiment, the invention relates to the pharmaceutical composition of the invention for use in the therapeutic treatment of dyskinesias induced by L-DOPA that comprises the administration of a therapeutically effective amount of said pharmaceutical composition simultaneously or sequentially to each administration. of L-DOPA.
    [0067] In a particular embodiment, the invention refers to a method for the treatment of dyskinesias induced by L-DOPA, where the patient is suffering from Parkinson's disease, the method comprises administering a therapeutically effective amount of Fasudil simultaneously or sequentially to each administration of L-DOPA.
    [0069] In a particular embodiment, the invention is directed to a pharmaceutical composition of the invention for use in a therapeutic treatment of dyskinesias induced by L-DOPA.
    [0070] One of the preferred routes of administration of the present invention is injectable, and thus in a particular embodiment the invention refers to the pharmaceutical composition as described above, the pharmaceutical form of which is suitable for injectable administration for use in the prevention or in the treatment of dyskinesias induced by L-DOPA.
    [0072] Another of the preferred routes of administration of the present invention is the oral route, and thus in a particular embodiment the invention refers to the pharmaceutical composition as described above, the pharmaceutical form of which is suitable for oral administration for use in the prevention or in the treatment of dyskinesias induced by L-DOPA.
    [0074] The following examples serve to illustrate the present invention and are not intended to limit it.
    [0076] Methods and experimental design
    [0078] In the following examples, rats of the Sprague-Dawley strain have been used, to which the neurotoxin 6-hydroxydopamine (6-OHDA) was injected following stereotaxic techniques in the medial forebrain bundle. This technique represents one of the most widespread models in the laboratory for the study of Parkinson's disease (PD) and its possible treatment routes (Ungerstedt U. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol. ( 1968) 5 (1): 107-10; Cenci MA, Crossman AR. Animal models of l-dopa-induced dyskinesia in Parkinson's disease. Mov Disord (2018) 33 (6): 889-899. Doi: 10.1002 / mds. 27337).
    [0080] To establish an animal model of dyskinesias, the animals were treated chronically with L-DOPA 6mg / kg (therapeutic dose) and benserazide (10mg / kg) for 3-4 weeks and during that period the abnormal involuntary movements ; AIMS) were evaluated through a specific test (Cenci MA, Lundblad M. Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice. Curr Protoc Neurosci. (2007) Chapter 9: Unit 9.25. Doi: 10.1002 / 0471142301).
    [0082] Example 1. Study of the dyskinetic model.
    [0083] A group of PD model animals was injected daily with different doses of L-DOPA (6mg / kg and 12mg / kg), until dyskinesia levels were stable (3-4 weeks). At the postmortem level, the striatum and substantia nigra were dissected and the expression levels of RhoA and ROCK were analyzed by western blot and real-time PCR.
    [0085] It was observed that in dyskinetic animals there was a significant increase in the levels of the RhoA protein and the ROCK protein. In addition, it was observed that in the animals treated with the highest dose of L-DOPA, and that showed earlier and more severe dyskinesias, the increase in the levels of these proteins was greater (see Figure 1).
    [0087] This experiment shows that the ROCK pathway is activated in dyskinetic animals.
    [0089] Example 2. Fasudil treatment during chronic L-DOPA treatment.
    [0090] In this study a group of rats treated with L-DOPA as described above was used as a control. One group was administered, in addition to L-DOPA, a ROCK pathway inhibitor, Fasudil, at a dose of 10 mg / kg / day, intraperitoneally (although it could be administered orally by adjusting the dose appropriately), starting 5 days before starting treatment with L-DOPA, and 30 minutes before each L-DOPA administration. Another group was administered, in addition to L-DOPA, Fasudil at a dose of 30 and 40 mg / kg / day, intraperitoneally with the same frequency as the previous group. In all cases, the treatment was carried out chronically for 3 weeks, and during this period abnormal involuntary movements were evaluated.
    [0091] In animals treated with a low dose of Fasudil (10 mg / kg) and L-DOPA, a statistically significant reduction in the development of dyskinesias was observed compared to the group of animals treated only with L-DOPA: approximately 25% of reduction in limb dyskinesias, 30% orolingual reduction and 35% axial reduction. The reduction of dyskinesias was observed from the 5th day.
    [0092] When the Fasudil dose was increased (30 mg / kg), a greater reduction in dyskinesias was observed in all dyskinetic components analyzed (70% oro-lingual, 60% axial and 60% extremity). Increasing the dose of Fasudil to 40 mg / kg, the reduction in dyskinesia reached 70%.
    [0093] At the end of the treatment, the L-DOPA dose was raised to 24mg / kg to check if Fasudil is also effective in conditions of severe dyskinesia, observing a large significant reduction of approximately 50% (see figure 2).
    [0096] This study shows that an inhibitor of the ROCK pathway, such as Fasudil, is useful in reducing the development of dyskinesias, even when they are caused by acute doses of L-DOPA.
    [0098] Example 3. Study of the interaction between the inhibition of the ROCK pathway and the therapeutic effect of L-DOPA.
    [0099] To investigate whether Fasudil could interfere with the therapeutic effect of L-DOPA, the cylinder test was performed, which is based on the analysis of the motor asymmetry suffered by animals after unilateral injury with 6-OHDA (Schallert T, Kozlowski DA, Humm JL, Cocke RR. Use-dependent structural events in recovery of function. Adv Neurol. (1997) 73: 229-38). In this experiment, the animals treated with Fasudil at all the doses studied (10, 30 and 40mg / kg) recovered the motor asymmetry caused by the injury 1h after the injection of L-DOPA, not observing differences with respect to those animals injected only with L-DOPA, indicating that this compound does not alter the therapeutic effect of L-DOPA (see Figure 3A-B). Furthermore, in experiments where rotational behavior was evaluated, no differences were observed in the rotations induced by L-DOPA in the animals treated with the different doses of Fasudil, showing that the reduction in dyskinesias is not produced by a reduction in the motor activity (see Figure 3C-E).
    [0100] This experiment demonstrates that the inhibition of the ROCK pathway, by administration of Fasudil, even at high doses, does not interfere with the therapeutic effect of L-DOPA.
    [0102] Example 4. Study of the therapeutic effect.
    [0103] A group of animals with unilateral lesions with 6-OHDA were treated daily with L-DOPA for 3 weeks and then treated with L-DOPA and Fasudil to investigate whether the inhibition of the ROCK pathway allows reducing dyskinesias once they are already established. . When a Fasudil dose of 10 mg / kg / day was used, no improvement was observed in the animals (up to 7 days of treatment).
    [0104] However, when a Fasudil dose of 40 mg / kg / day was used, there was a reduction in dyskinesias of around 45% from the third day of treatment. Increasing the dose of L-DOPA to 24 mg / kg causing a condition of severe dyskinesia, the reduction was even greater, of approximately 50%, which was maintained until the end of the treatment (see figure 4).
    权利要求:
    Claims (10)
    [1]
    1. - Pharmaceutical composition comprising a compound capable of inhibiting the ROCK pathway, for use in the prophylactic or therapeutic treatment of dyskinesias induced by L-DOPA.
    [2]
    2. - The pharmaceutical composition for use according to claim 1, wherein the compound capable of inhibiting the ROCK pathway is selected from Fasudil and its derivatives, Ripasudil, Y-27632, Y-32885, AMA-0076, AR-12286, AR-13324 (Rhopressa), KD-025 (Slx2119), LX7101, PG-324 (Roclatan), SAR407899.
    [3]
    3. - The pharmaceutical composition for use according to claim 1, wherein the compound capable of inhibiting the ROCK pathway is Fasudil, a pharmaceutically acceptable salt thereof, or an analog thereof.
    [4]
    4. - The composition for use according to any of the preceding claims, wherein said composition is administered in a pharmaceutical form suitable for oral or injectable administration.
    [5]
    5. - The pharmaceutical composition for use according to claim 1, where the compound is Fasudil or a pharmaceutically acceptable salt thereof, the pharmaceutical form of which is suitable for oral or injectable administration for use in the prevention of dyskinesias induced by L-DOPA .
    [6]
    6. - The composition according to any of the preceding claims, for use in the prophylactic treatment of dyskinesias induced by L-DOPA comprising: (i) the administration of said pharmaceutical composition in a therapeutically effective amount prior to the start of treatment with L- DOPA, and (ii) the administration of a therapeutically effective amount of said pharmaceutical composition simultaneously or sequentially to each administration of L-DOPA.
    [7]
    7. - The pharmaceutical composition for use according to claim 6, wherein the compound is Fasudil or a pharmaceutically acceptable salt thereof whose pharmaceutical form is suitable for oral or injectable administration.
    [8]
    8. - The composition according to any of claims 1-5, for use in the therapeutic treatment of dyskinesias induced by L-DOPA which comprises the administration of a therapeutically effective amount of said pharmaceutical composition simultaneously or sequentially to each administration of L-DOPA .
    [9]
    9. - Pharmaceutical composition for use according to claim 8, wherein the compound is Fasudil or a pharmaceutically acceptable salt thereof whose pharmaceutical form is suitable for oral or injectable administration.
    [10]
    10. - Pharmaceutical composition for use according to claim 1, wherein the compound is Fasudil or a pharmaceutically acceptable salt thereof, the pharmaceutical form of which is suitable for oral or injectable administration for use in the treatment of dyskinesias induced by L-DOPA.
    1
    类似技术:
    公开号 | 公开日 | 专利标题
    Fujikake et al.2018|Association between autophagy and neurodegenerative diseases
    Liu et al.2015|Activation of α7 nicotinic acetylcholine receptors protects astrocytes against oxidative stress-induced apoptosis: implications for Parkinson's disease
    ES2696598T3|2019-01-17|Balancer compounds for use in the treatment of pain
    Kim et al.2014|Inhibitory effects of isoquinoline alkaloid berberine on ischemia-induced apoptosis via activation of phosphoinositide 3-kinase/protein kinase B signaling pathway
    Decressac et al.2013|mTOR inhibition alleviates L-DOPA-induced dyskinesia in parkinsonian rats
    Manaenko et al.2013|PAR-1 antagonist SCH79797 ameliorates apoptosis following surgical brain injury through inhibition of ASK1-JNK in rats
    Wei et al.2015|Probenecid protects against cerebral ischemia/reperfusion injury by inhibiting lysosomal and inflammatory damage in rats
    Fiorentini et al.2013|Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease
    Dong et al.2017|Neuroprotection of Ro25-6981 against ischemia/reperfusion-induced brain injury via inhibition of autophagy
    Jia et al.2017|Prdx6 upregulation by curcumin attenuates ischemic oxidative damage via SP1 in rats after stroke
    Li et al.2014|Low-dose endothelial monocyte-activating polypeptide-II increases permeability of blood–tumor barrier by caveolae-mediated transcellular pathway
    Li et al.2015|Blockade of high mobility group box-1 signaling via the receptor for advanced glycation end-products ameliorates inflammatory damage after acute intracerebral hemorrhage
    Yue et al.2017|Intranasal administration of GDNF protects against neural apoptosis in a rat model of Parkinson’s disease through PI3K/Akt/GSK3β pathway
    JP2009523157A|2009-06-18|Compounds for the treatment of ischemia and neurodegeneration
    Yang et al.2012|Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats
    Mao et al.2021|The role of PARP1 in neurodegenerative diseases and aging
    F Shevtsova et al.2017|Mitochondrial permeability transition pore as a suitable targ et for neuroprotective agents against Alzheimer's disease
    Sasaki et al.2016|Evaluation of canthinone alkaloids as cerebral protective agents
    Kwan et al.2020|Ondansetron, a highly selective 5-HT3 receptor antagonist, reduces L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease
    ES2804076B2|2021-07-12|PHARMACEUTICAL COMPOSITION FOR USE IN THE PROPHYLACTIC AND / OR THERAPEUTIC TREATMENT OF L-DOPA-INDUCED DYSKINESIA
    Cicenas2015|JNK inhibitors: is there a future?
    US20040127571A1|2004-07-01|Method of Treating Leukemia with a Combination of Suberoylanilide Hydromaxic Acid and Imatinib Mesylate
    Moraes et al.2021|Modified glutamatergic postsynapse in neurodegenerative disorders
    Lane et al.2010|Pre-treatment with dopamine agonists influence L-dopa mediated rotations without affecting abnormal involuntary movements in the 6-OHDA lesioned rat
    Ye et al.2017|Anesthetic effects on autophagy
    同族专利:
    公开号 | 公开日
    ES2804076B2|2021-07-12|
    US20210393646A1|2021-12-23|
    WO2021019116A1|2021-02-04|
    CA3145360A1|2021-02-04|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    法律状态:
    2021-02-03| BA2A| Patent application published|Ref document number: 2804076 Country of ref document: ES Kind code of ref document: A1 Effective date: 20210203 |
    2021-07-12| FG2A| Definitive protection|Ref document number: 2804076 Country of ref document: ES Kind code of ref document: B2 Effective date: 20210712 |
    优先权:
    申请号 | 申请日 | 专利标题
    ES201930713A|ES2804076B2|2019-07-31|2019-07-31|PHARMACEUTICAL COMPOSITION FOR USE IN THE PROPHYLACTIC AND / OR THERAPEUTIC TREATMENT OF L-DOPA-INDUCED DYSKINESIA|ES201930713A| ES2804076B2|2019-07-31|2019-07-31|PHARMACEUTICAL COMPOSITION FOR USE IN THE PROPHYLACTIC AND / OR THERAPEUTIC TREATMENT OF L-DOPA-INDUCED DYSKINESIA|
    CA3145360A| CA3145360A1|2019-07-31|2020-07-24|Pharmaceutical composition for use in the prophylactic and/or therapeutic treatment of l-dopa-induced dyskinesia|
    PCT/ES2020/070482| WO2021019116A1|2019-07-31|2020-07-24|Pharmaceutical composition for use in the prophylactic and/or therapeutic treatment of l-dopa-induced dyskinesia|
    US17/406,689| US20210393646A1|2019-07-31|2021-08-19|Pharmaceutical composition for use in the prophylactic and/or therapeutic treatment of l-dopa-induced dyskinesia|
    [返回顶部]